MarketPeel
Insider Trading Intelligence
Pricing
…
TB

Thomas W. Beetham

KNSA
EVP & CHIEF LEGAL OFFICER · KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC · CIK 0001741382
FILING MIX · LIFETIME54%/46%
BUYS
15
SELLS
13
TOTAL VALUE
$2.43M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
17,648
AVG SELL PX
$22.44
TRADE KIND
SHOWING 28 / 28
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Thomas W. Beetham, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+44.44%+1.41%+1.53%-0.12%+0.97%—
14d9+55.56%-0.50%+0.59%-1.09%-0.13%—
30d9+44.44%-6.30%+0.54%-6.84%-2.28%—
60d9+55.56%-3.13%+7.14%-10.27%-11.19%—
90d9+44.44%-8.23%+8.20%-16.43%-20.58%—
180d9+77.78%-19.38%+16.87%-36.25%-38.69%—
1y9+77.78%-25.03%+36.47%-61.50%-73.75%—
2y9(1 pending)+100.00%-50.09%+39.62%-89.71%-89.03%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KNSA · 4,287 shares · as of Mar 20, 2021
075,000150,000225,000300,0002021SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 15 buys / 13 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
Chief Operating Officer
3,138$29.32$92.0K13,271Mar 3, 2026Mar 4, 2026 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
Chief Operating Officer
9,409——16,409Mar 3, 2026Mar 4, 2026 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
Chief Operating Officer
9,409——28,227Mar 3, 2026Mar 4, 2026 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
Chief Operating Officer
3,048$30.19$92.0K13,361Mar 3, 2026Mar 9, 2026 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
35,300——35,300Mar 2, 2026Mar 4, 2026 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
176,550——176,550Mar 2, 2026Mar 4, 2026 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
37,636——37,636Mar 3, 2025Mar 4, 2025 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
225,814——225,814Mar 3, 2025Mar 4, 2025 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
Chief Operating Officer
5,000$23.41$117.0K6,000Sep 27, 2024Sep 30, 2024 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
474,400——474,400Oct 30, 2023Nov 1, 2023 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASEGRANT
Stock grant
5,855——5,855Mar 20, 2021Mar 23, 2021 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASEGRANT
Stock grant
4,287——4,287Mar 20, 2021Mar 23, 2021 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASEGRANT
Stock grant
8,769——8,769Mar 16, 2021Mar 18, 2021 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASEGRANT
Stock grant
52,611——52,611Mar 16, 2021Mar 18, 2021 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASE
EVP & Chief Legal Officer
300,000——300,000Feb 3, 2021Feb 5, 2021 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
2,477$22.09$54.7K297,523Feb 3, 2021Feb 5, 2021 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
300,000——114,157Feb 3, 2021Feb 5, 2021 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASEGRANT
Stock grant
75,000——75,000Sep 10, 2020Sep 14, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
26,734$25.32$676.9K2,855Jul 1, 2020Jul 2, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
2,855$25.84$73.8K0Jul 1, 2020Jul 2, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
13,752$25.07$344.8K29,589Jun 10, 2020Jun 12, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASE
EVP & Chief Legal Officer
13,752$1.59$21.9K43,341Jun 10, 2020Jun 12, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
13,752——112,189Jun 10, 2020Jun 12, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
955$20.44$19.5K29,589Apr 21, 2020Apr 22, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
1,563$19.56$30.6K30,544Apr 21, 2020Apr 22, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
47,423$19.06$903.9K32,107Apr 20, 2020Apr 22, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASEGRANT
Stock grant
75,000——75,000Mar 13, 2020Mar 17, 2020 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SALE
EVP & Chief Legal Officer
59$18.58$1.1K79,530Feb 14, 2020Feb 19, 2020 ↗View →
Other insiders · KNSA
Loading peer insiders…
About this filer
CIK 0001741382
ROLE
EVP & Chief Legal Officer
PRIMARY
KNSA
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001741382DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback